Deutsche Bank AG Acquires Shares of 45,109 Enliven Therapeutics, Inc. $ELVN

Key Points

• Deutsche Bank acquired 45,109 Enliven Therapeutics shares during the second quarter, valued at approximately $2.3 million. Institutional investors and hedge funds collectively own 95.08% of ELVN.
• Enliven shares opened at $60.50, near their 12-month high of $62.32, despite the company reporting a quarterly loss of $0.49 per share that missed analyst expectations.
• Analysts maintain a generally positive outlook, with eight Buy ratings and one Sell rating, a “Moderate Buy” consensus, and an average price target of $75. However, insiders sold nearly 197,000 shares worth $11.3 million over the past 90 days.

Deutsche Bank AG acquired a new position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 45,109 shares of the company's stock, valued at approximately $2,289,000. Deutsche Bank AG owned approximately 0.07% of Enliven Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Dimensional Fund Advisors LP increased its position in Enliven Therapeutics by 70.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 681,715 shares of the company's stock valued at $26,714,000 after acquiring an additional 282,822 shares in the last quarter. Avidity Partners Management LP lifted its position in shares of Enliven Therapeutics by 185.1% during the first quarter. Avidity Partners Management LP now owns 400,000 shares of the company's stock worth $15,680,000 after purchasing an additional 259,700 shares in the last quarter. Stempoint Capital LP acquired a new position in shares of Enliven Therapeutics during the first quarter worth approximately $14,247,000. Tema ETFs LLC grew its stake in shares of Enliven Therapeutics by 41.0% during the second quarter. Tema ETFs LLC now owns 60,694 shares of the company's stock valued at $3,080,000 after purchasing an additional 17,638 shares during the last quarter. Finally, TimesSquare Capital Management LLC bought a new stake in shares of Enliven Therapeutics during the second quarter valued at approximately $13,263,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Enliven Therapeutics Stock Down 0.6%

Shares of ELVN stock opened at $60.50 on Friday. Enliven Therapeutics, Inc. has a 12-month low of $14.78 and a 12-month high of $62.32. The firm has a fifty day moving average of $54.36 and a 200-day moving average of $42.99. The firm has a market capitalization of $4.43 billion, a price-to-earnings ratio of -36.23 and a beta of 0.27.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Research analysts expect that Enliven Therapeutics, Inc. will post -1.69 earnings per share for the current year.

Insider Transactions at Enliven Therapeutics

In related news, Director Lori Anne Kunkel sold 10,000 shares of the business's stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $50.49, for a total value of $504,900.00. Following the completion of the transaction, the director directly owned 41,884 shares in the company, valued at approximately $2,114,723.16. The trade was a 19.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mika K. Derynck sold 158,795 shares of the stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $60.21, for a total value of $9,561,046.95. Following the sale, the director directly owned 87,373 shares of the company's stock, valued at approximately $5,260,728.33. The trade was a 64.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 196,849 shares of company stock valued at $11,344,257 over the last 90 days. 3.00% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on ELVN shares. Guggenheim lowered their price target on shares of Enliven Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a report on Thursday, August 6th. Mizuho increased their price objective on Enliven Therapeutics from $62.00 to $73.00 and gave the company an "outperform" rating in a research report on Tuesday, August 18th. HC Wainwright lifted their target price on Enliven Therapeutics from $56.00 to $64.00 and gave the company a "buy" rating in a research note on Thursday, July 9th. Wall Street Zen downgraded Enliven Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 8th. Finally, Barclays assumed coverage on Enliven Therapeutics in a report on Tuesday, August 18th. They issued an "overweight" rating and a $78.00 price target on the stock. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $75.00.

Enliven Therapeutics Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

Want to see what other hedge funds are holding ELVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source